Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia

ABSTRACT Olverembatinib is approved in China to treat patients with chronic‐ or accelerated‐phase chronic myeloid leukemia (CML‐CP or CML‐AP) with T315I mutations and CML‐CP that is resistant and/or intolerant to first‐ and second‐generation tyrosine kinase inhibitors. The objective of this study wa...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hengbang Wang, Yun Yang, Zi Chen, Min Yu, Lixin Jiang, Lichuang Men, Hua Yan, Dajun Yang, Yifan Zhai
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-05-01
coleção:	Clinical and Translational Science
Assuntos:	BCR::ABL1 tyrosine kinase inhibitor (TKI) chronic myeloid leukemia (CML) food effect
Acesso em linha:	https://doi.org/10.1111/cts.70545
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!